Open AccessEfficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients
Author(s) -
Claudia Djambas Khayat,
Genadi Iosava,
I. P. Romashevskaya,
Oleksandra Stasyshyn,
Marta Julia López,
Maria Teresa Pompa,
Tobias Rogosch,
Wilfried Seifert
Publication year - 2021
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s299130
Subject(s) - medicine , von willebrand factor , pharmacokinetics , gastroenterology , titer , von willebrand disease , adverse effect , immunology , antibody , platelet
Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII; VONCENTO ® , CSL Behring) is a high-concentration, low-volume, high-purity concentrate, with a high level of VWF high-molecular-weight multimers and a VWF/FVIII ratio of ~2.4:1.